{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T09:17:43Z","timestamp":1720689463761},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.3816\/clm.2008.s.016","type":"journal-article","created":{"date-parts":[[2008,12,16]],"date-time":"2008-12-16T02:03:23Z","timestamp":1229393003000},"page":"S193-S198","source":"Crossref","is-referenced-by-count":0,"special_numbering":"S5","title":["Novel Antibody Approaches for T-Cell Lymphomas"],"prefix":"10.3816","volume":"8","author":[{"suffix":"Jr.","given":"Oscar B.","family":"Goodman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nam H.","family":"Dang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2008.s.016_bib1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"Kohler","year":"1975","journal-title":"Nature"},{"key":"10.3816\/CLM.2008.s.016_bib2","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1182\/blood-2002-07-2206","article-title":"CD2 engagement induces dendritic cell activation: implications for immune surveillance and T-cell activation","volume":"102","author":"Crawford","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.016_bib3","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.4049\/jimmunol.160.8.3797","article-title":"Potent apoptotic signaling and subsequent unresponsiveness induced by a single CD2 mAb (BTI-322) in activated human peripheral T cells","volume":"160","author":"Dumont","year":"1998","journal-title":"J Immunol"},{"key":"10.3816\/CLM.2008.s.016_bib4","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1021\/cb6002515","article-title":"Mechanisms of cellular avidity regulation in CD2-CD58-mediated T cell adhesion","volume":"1","author":"Zhu","year":"2006","journal-title":"ACS Chem Biol"},{"key":"10.3816\/CLM.2008.s.016_bib5","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(02)00516-2","article-title":"The Wiskott-Aldrich syndrome protein acts downstream of CD2 and the CD2AP and PSTPIP1 adaptors to promote formation of the immunological synapse","volume":"18","author":"Badour","year":"2003","journal-title":"Immunity"},{"key":"10.3816\/CLM.2008.s.016_bib6","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1084\/jem.183.1.169","article-title":"The SH3 domain of p56lck binds to proline-rich sequences in the cytoplasmic domain of CD2","volume":"183","author":"Bell","year":"1996","journal-title":"J Exp Med"},{"key":"10.3816\/CLM.2008.s.016_bib7","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1002\/j.1460-2075.1991.tb07687.x","article-title":"Pairwise, cooperative and inhibitory interactions describe the assembly and probable structure of the T-cell antigen receptor","volume":"10","author":"Manolios","year":"1991","journal-title":"EMBO J"},{"key":"10.3816\/CLM.2008.s.016_bib8","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/eji.1830200337","article-title":"Hypothermia and hypoglycemia induced by anti-CD3 monoclonal antibody in mice: role of tumor necrosis factor","volume":"20","author":"Alegre","year":"1990","journal-title":"Eur J Immunol"},{"key":"10.3816\/CLM.2008.s.016_bib9","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1182\/blood.V99.8.2712","article-title":"A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease","volume":"99","author":"Carpenter","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.016_bib10","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/346425a0","article-title":"Adhesion receptors of the immune system","volume":"346","author":"Springer","year":"1990","journal-title":"Nature"},{"key":"10.3816\/CLM.2008.s.016_bib11","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1084\/jem.162.4.1294","article-title":"Chess L Perturbation of the T4 molecule transmits a negative signal to T cells","volume":"162","author":"Bank","year":"1985","journal-title":"J Exp Med"},{"key":"10.3816\/CLM.2008.s.016_bib12","doi-asserted-by":"crossref","first-page":"9945","DOI":"10.1158\/0008-5472.CAN-07-1148","article-title":"A human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of T-cell signaling by a dual mechanism with potent Fc-dependent effector activity","volume":"67","author":"Rider","year":"2007","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2008.s.016_bib13","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1002\/eji.1830231043","article-title":"Chimaeric anti-CD4 monoclonal antibody cross-linked by monocyte Fc gamma receptor mediates apoptosis of human CD4 lymphocytes","volume":"23","author":"Choy","year":"1993","journal-title":"Eur J Immunol"},{"key":"10.3816\/CLM.2008.s.016_bib14","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/sj.jid.5700122","article-title":"CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma","volume":"126","author":"Talpur","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.3816\/CLM.2008.s.016_bib15","doi-asserted-by":"crossref","first-page":"5587","DOI":"10.1158\/1078-0432.CCR-0721-03","article-title":"Degree of CD25 expression in T-cell lymphoma is dependent on tissue site: implications for targeted therapy","volume":"10","author":"Jones","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2008.s.016_bib16","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1182\/blood-2006-12-062943","article-title":"Direct inhibition of CD40L expression can contribute to the clinical efficacy of daclizumab independently of its effects on cell division and Th1\/Th2 cytokine production","volume":"109","author":"Snyder","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.016_bib17","first-page":"2031","article-title":"In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299","volume":"7","author":"Ho","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2008.s.016_bib18","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1309\/U1Y6-J4AG-5M4M-7AYV","article-title":"Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood","volume":"115","author":"Jones","year":"2001","journal-title":"Am J Clin Pathol"},{"key":"10.3816\/CLM.2008.s.016_bib19","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1046\/j.1365-2141.2003.04365.x","article-title":"T-large granular lymphocyte lymphoproliferative disorder: expression of CD26 as a marker of clinically aggressive disease and characterization of marrow inhibition","volume":"121","author":"Dang","year":"2003","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2008.s.016_bib20","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/(SICI)1097-0320(19980215)34:1<30::AID-CYTO5>3.0.CO;2-I","article-title":"CD26 expression and dipeptidyl peptidase IV activity in an aggressive hepatosplenic T-cell lymphoma","volume":"34","author":"Ruiz","year":"1998","journal-title":"Cytometry"},{"key":"10.3816\/CLM.2008.s.016_bib21","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1182\/blood.V86.12.4617.bloodjournal86124617","article-title":"The expression of CD26 and CD40 ligand is mutually exclusive in human T-cell non-Hodgkin's lymphomas\/leukemias","volume":"86","author":"Carbone","year":"1995","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.016_bib22","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/clim.1998.4636","article-title":"CD30 in normal and neoplastic cells","volume":"90","author":"Chiarle","year":"1999","journal-title":"Clin Immunol"},{"key":"10.3816\/CLM.2008.s.016_bib23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/299065a0","article-title":"Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells","volume":"299","author":"Schwab","year":"1982","journal-title":"Nature"},{"key":"10.3816\/CLM.2008.s.016_bib24","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood-2007-07-099317","article-title":"A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies","volume":"111","author":"Bartlett","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.016_bib25","doi-asserted-by":"crossref","first-page":"6703","DOI":"10.4049\/jimmunol.165.12.6703","article-title":"CD30 shedding from Karpas 299 lymphoma cells is mediated by TNF-alpha-converting enzyme","volume":"165","author":"Hansen","year":"2000","journal-title":"J Immunol"},{"key":"10.3816\/CLM.2008.s.016_bib26","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/ijc.10182","article-title":"Inhibition of metalloproteinases enhances the internalization of anti-CD30 antibody Ki-3 and the cytotoxic activity of Ki-3 immunotoxin","volume":"98","author":"Hansen","year":"2002","journal-title":"Int J Cancer"},{"key":"10.3816\/CLM.2008.s.016_bib27","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1182\/blood.V62.4.873.873","article-title":"Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement","volume":"62","author":"Hale","year":"1983","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.016_bib28","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3324\/haematol.10767","article-title":"Expression of CD52 in peripheral T-cell lymphoma","volume":"92","author":"Piccaluga","year":"2007","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2008.s.016_bib29","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1158\/1078-0432.CCR-06-1275","article-title":"Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H)","volume":"12","author":"Rodig","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2008.s.016_bib30","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1182\/blood-2006-12-062877","article-title":"Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma","volume":"109","author":"Kim","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.016_bib31","first-page":"999a","article-title":"Zanolimumab (HuMax-CD4TM), a fully human monoclonal antibody: efficacy and safety in patients with relapsed or treatment-refractory non-cutaneous CD4+ T-cell lymphoma","volume":"110","author":"d'Amore","year":"2007","journal-title":"Blood"},{"issue":"16 suppl","key":"10.3816\/CLM.2008.s.016_bib32","first-page":"174s","article-title":"Phase I trial of siplizumab in CD2-positive lymphoproliferative disease","volume":"23","author":"Janik","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2008.s.016_bib33","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1200\/JCO.2002.06.119","article-title":"Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine","volume":"20","author":"Rai","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2008.s.016_bib34","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1182\/blood.V98.6.1721","article-title":"High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H","volume":"98","author":"Dearden","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.016_bib35","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","article-title":"Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/Sezary syndrome","volume":"101","author":"Lundin","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.016_bib36","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0046-8177(84)80194-X","article-title":"Virus-associated hemophagocytic syndrome due to Epstein-Barr virus","volume":"15","author":"Reisman","year":"1984","journal-title":"Hum Pathol"},{"key":"10.3816\/CLM.2008.s.016_bib37","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3324\/haematol.11127","article-title":"Low-dose intermittent alemtuzumab in the treatment of Sezary syndrome: clinical and immunologic findings in 14 patients","volume":"92","author":"Bernengo","year":"2007","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2008.s.016_bib38","first-page":"943","article-title":"Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen [in Chinese]","volume":"23","author":"Peng","year":"2004","journal-title":"Ai Zheng"},{"key":"10.3816\/CLM.2008.s.016_bib39","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.3348.3348","article-title":"A pilot trial of campath-1H and dose-Adjusted EPOCH in CD52-expressing aggressive T-cell malignancies","volume":"106","author":"Janik","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.016_bib40","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/00007890-199908270-00020","article-title":"HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro","volume":"68","author":"Cole","year":"1999","journal-title":"Transplantation"},{"key":"10.3816\/CLM.2008.s.016_bib41","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.bbmt.2005.03.002","article-title":"A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease","volume":"11","author":"Carpenter","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.3816\/CLM.2008.s.016_bib42","unstructured":"Clinicaltrials.gov [Web site]. Monoclonal antibody therapy in treating patients with advanced or recurrent lymphoma. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00006009?term=NCT00006009&rank=1"},{"key":"10.3816\/CLM.2008.s.016_bib43","unstructured":"Clinicaltrials.gov [Web site]. MDX-060 in Patients with relapsed or refractory classic systemic or primary cutaneous anaplastic large cell lymphoma. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00298467?term=NCT00298467&rank=1"},{"key":"10.3816\/CLM.2008.s.016_bib44","doi-asserted-by":"crossref","first-page":"771a","DOI":"10.1182\/blood.V108.11.2727.2727","article-title":"A phase I open label dose escalation study to evaluate MEDI-507 in patients with CD2-positive T-cell lymphoma\/leukemia","volume":"108","author":"Casale","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.016_bib45","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1200\/JCO.2007.12.9098","article-title":"Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia","volume":"25","author":"Hillmen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2008.s.016_bib46","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2003-10-3389","article-title":"A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas","volume":"103","author":"Enblad","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.016_bib47","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","article-title":"Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial","volume":"110","author":"Gallamini","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.016_bib48","doi-asserted-by":"crossref","first-page":"769a","DOI":"10.1182\/blood.V108.11.2721.2721","article-title":"A phase II immunochemotherapy study with alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas","volume":"108","author":"Weidmann","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.016_bib49","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/00007890-199908270-00018","article-title":"A humanized anti-CD3 antibody, HuM291, with low mitogenic activity, mediates complete and reversible T-cell depletion in chimpanzees","volume":"68","author":"Hsu","year":"1999","journal-title":"Transplantation"},{"key":"10.3816\/CLM.2008.s.016_bib50","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1200\/JCO.2006.07.8972","article-title":"Phase I\/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma","volume":"25","author":"Ansell","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2008.s.016_bib51","doi-asserted-by":"crossref","first-page":"773a","DOI":"10.1182\/blood.V108.11.2733.2733","article-title":"Phase II preliminary results of SGN-30 (anti-CD30 mAB) in patients with CD30+ lymphoproliferative disorders","volume":"108","author":"Duvic","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2008.s.016_bib52","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1200\/JCO.2000.18.8.1622","article-title":"Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies","volume":"18","author":"Kreitman","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2008.s.016_bib53","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/07357900701360096","article-title":"Denileukin diftitox as novel targeted therapy for lymphoid malignancies","volume":"25","author":"Wong","year":"2007","journal-title":"Cancer Invest"},{"key":"10.3816\/CLM.2008.s.016_bib54","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2141.2006.06457.x","article-title":"Phase II trial of denileukin diftitox for relapsed\/refractory T-cell non-Hodgkin lymphoma","volume":"136","author":"Dang","year":"2007","journal-title":"Br J Haematol"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011702803?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011702803?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T23:21:55Z","timestamp":1684797715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011702803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":54,"alternative-id":["S1557919011702803"],"URL":"https:\/\/doi.org\/10.3816\/clm.2008.s.016","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}